ReviewDrugs & aging2016
Clinical Applications of Dexamethasone for Aged Eyes.
Review in Drugs & aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of preoperative doses of betamethasone acetate 0.1% on dry eye control after cataract surgery.Indian journal of ophthalmology · 2020Trial
- Angiotensin (1-7)-based Proteomimetic Polymers as Topicals for the Remediation and Repair of the Cornea following Injury.bioRxiv : the preprint server for biology · 2026Article
- Intravitreal Sustained Release of Dexamethasone from a Self-Healing Injectable Hydrogel: An In Vivo Safety and Release Study.Molecular pharmaceutics · 2025Article
- Unveiling ferroptosis genes and inhibitors in diabetic retinopathy through single-cell analysis and docking simulations.Biochemistry and biophysics reports · 2025Article
- Article
- Inflammation mechanism and anti-inflammatory therapy of dry eye.Frontiers in medicine · 2024Review
- Self-Healing Thermosensitive Hydrogel for Sustained Release of Dexamethasone for Ocular Therapy.ACS polymers Au · 2023Article
- A One-Week Course of Levofloxacin/Dexamethasone Eye Drops: A Review on a New Approach in Managing Patients After Cataract Surgery.Ophthalmology and therapy · 2022Review
- Pharmacokinetics of Pullulan-Dexamethasone Conjugates in Retinal Drug Delivery.Pharmaceutics · 2021Article
- Characterization of Zinc Oxide Nanoparticle Cross-Linked Collagen Hydrogels.Gels (Basel, Switzerland) · 2020Article
- Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2020Article
- Results from the Population-Based Gutenberg Health Study Revealing Four Altered Autoantibodies in Retinal Vein Occlusion Patients.Journal of ophthalmology · 2020Article
- Mitochondrial Dynamics Impairment in Dexamethasone-Treated Neuronal Cells.Neurochemical research · 2019Article
- Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Dexamethasone distribution characteristic following controllable continuous sub-tenon drug delivery in rabbit.Drug delivery · 2017Article
- Cyclodextrin-Based Nanohydrogels Containing Polyamidoamine Units: A New Dexamethasone Delivery System for Inflammatory Diseases.Gels (Basel, Switzerland) · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of severe eye problems has been found to increase significantly with age, particularly between the fifth and sixth decades of life. Cataracts, dry eye, neovascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusion (RVO) are very common and very different age-related ocular diseases that reduce the patient's quality of life. The rationale for using corticosteroids to treat anterior and posterior ocular segment diseases is driven by inflammation. Dexamethasone, one of the most powerful corticosteroids available, is widely used for topical or intravitreal administration. Topical dexamethasone has proven efficacy for the management of postoperative inflammation in the anterior segment after cataract surgery and symptom relief in dry-eye disease. A new sustained-release 700 µg dexamethasone intravitreal implant (DEX) was recently approved for the treatment of macular edema following RVO, diabetic macular edema, or non-infectious uveitis, and its use is increasing, especially when other therapeutic agents have failed. The most common side effects are increased intraocular pressure and cataract formation. The potency of DEX, alone or in combination with other agents, makes DEX a promising option for treating several retinal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.